Following National Advertising Division Challenge, NutriDrip Voluntarily Modified or Discontinued Certain NutrIMMUNITY IV Drip Therapy Claims

New York, NY – May 30, 2024 – Following a challenge brought by BBB National Programs’ National Advertising Division as part of its routine monitoring program, NutriDrip/JMB Medical Group, PLLC discontinued certain advertising claims used to promote its NutrIMMUNITY IV Drip Therapy.

NutriDrip offers intravenous nutritional therapy treatment via fluids, electrolytes, vitamins, and minerals to deliver nutrients to the body.

The National Advertising Division (NAD) challenged a number of health-related claims, including claims that the Drip Therapy boosts immune defenses. NAD also challenged a testimonial relating to the efficacy of the drip therapy. 

NutriDrip objected to NAD’s jurisdiction on the grounds that its advertising is not “national advertising” as it is only directed to consumers in New York City and Las Vegas where its clinics are located. However, NAD determined that it has jurisdiction over the challenged claims because NutriDrip’s website is accessible from anywhere and NutriDrip’s advertising targets travelers, a national audience, for NutriDrip locations in or near hotels in both cities. 

NutriDrip informed NAD that it is permanently discontinuing or modifying the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the claims, for compliance purposes, as though NAD recommended their discontinuance or modification. 

In its advertiser statement, NutriDrip stated that it “agrees to comply and thanks NAD for its consideration.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB procedures, this release shall not be used for advertising or promotional purposes.